Insulin-like growth factor (IGF) and epidermal growth factor (EGF) receptors as therapeutic targets in metastatic renal cell carcinoma
| Autor: | R. J. Hauke, J. E. Elkahwaji |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Cancer Research
Chemotherapy Kidney business.industry Angiogenesis medicine.medical_treatment urologic and male genital diseases medicine.disease female genital diseases and pregnancy complications Nephrectomy Insulin-like growth factor medicine.anatomical_structure Oncology Renal cell carcinoma Epidermal growth factor Immunology Cancer research Medicine Hormonal therapy business |
| Zdroj: | Journal of Clinical Oncology. 28:e15113-e15113 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2010.28.15_suppl.e15113 |
| Popis: | e15113 Background: Renal cell carcinoma (RCC) is associated with mutation or loss of function of the von Hippel-Lindau gene resulting in hypoxia-inducible factor 1-alpha accumulation and production of growth factors involved in proliferation and angiogenesis. Radical nephrectomy remains the primary treatment option for two thirds of RCC patients who present with tumors confined to the kidney. However, approximately one half of patients will develop metastatic RCC. Treatment of RCC has been hampered by its resistance to most chemotherapy and hormonal therapy, although selected patients have long term remission from high dose of interleukin-2. Despite the recent availability of several active targeted agents in this disease, therapy is not curative. As a result, there is continued demand for improving therapy for metastatic disease to enhance both clinical benefits and patients overall survival. The EGF and IGF-1 pathways have been implicated as potential therapeutic targets in RCC. The objective of this st... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|